Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations

Marco Bongiovanni; Paul Thoueille; Beatrice Barda; Thomas Mercier; Catia Marzolini; Niccolò Ramponi; Eva Choong; Marco Cantù; Laurent A Decosterd; Enos Bernasconi

doi:10.1007/s10096-024-04844-5

Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations

Eur J Clin Microbiol Infect Dis. 2024 May 14. doi: 10.1007/s10096-024-04844-5. Online ahead of print.

Authors

Marco Bongiovanni^{1

2}, Paul Thoueille^{3

4}, Beatrice Barda^{5

4}, Thomas Mercier^{3

4}, Catia Marzolini^{3

4}, Niccolò Ramponi^{5

4}, Eva Choong^{3

4}, Marco Cantù^{4

6}, Laurent A Decosterd^{3

4}, Enos Bernasconi^{5

4

7

8}

Affiliations

¹ Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland. Marco.Bongiovanni@eoc.ch.
² Division of Infectious Diseases and Hospital Epidermiology, University Hospital Basel, Basel, Switzerland. Marco.Bongiovanni@eoc.ch.
³ Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁴ Division of Infectious Diseases and Hospital Epidermiology, University Hospital Basel, Basel, Switzerland.
⁵ Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.
⁶ Istituto di Medicina di Laboratorio EOLAB Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
⁷ University of Geneva, Geneva, Switzerland.
⁸ University of Southern Switzerland, Lugano, Switzerland.

PMID: 38740656
DOI: 10.1007/s10096-024-04844-5

No abstract available

Publication types

Letter